Terray Therapeutics, a biotechnology company improving human health by transforming the speed, cost, and success rate of small molecule drug development using computation integrated with novel data at scale, has announced Series B funding of $120 million. The funding will progress internal programs into clinical trials and further enhance Terray's integrated AI platform, tNova, which it uses to power both internal and partnered programs.

The round was led by new investor Bedford Ridge Capital and existing investor NVentures (NVIDIA's venture capital arm), with participation from new and existing investors including Maverick Capital, Goldcrest Capital, Madrona Ventures, Two Sigma Ventures, XTX Ventures, Digitalis Ventures, and Alexandria Ventures. Sid Shenai, who partnered with Bedford Ridge Capital on this financing, will join Terray's Board of Directors.

Terray is a biotechnology company with the technology, data, and mindset to radically change the way we discover and develop small molecule therapeutics. The company explores molecules and targets with a sophisticated integration of ultra-high throughput experimentation, generative AI, biology, medicinal chemistry, automation, and nanotechnology. Terray's platform uniquely blends experimentation and computation to deliver on the promise of generative AI for small molecule discovery-finding solutions to the toughest therapeutic challenges.